MCID: THL013
MIFTS: 55

Thalassemia, Hispanic Gamma-Delta-Beta malady

Categories: Genetic diseases, Rare diseases, Immune diseases, Blood diseases, Nephrological diseases, Endocrine diseases

Aliases & Classifications for Thalassemia, Hispanic Gamma-Delta-Beta

About this section
Sources:
49OMIM, 11diseasecard, 45NIH Rare Diseases, 10Disease Ontology, 22GeneTests, 23Genetics Home Reference, 12DISEASES, 67UniProtKB/Swiss-Prot, 65UMLS, 68Wikipedia, 21GeneReviews, 47Novoseek, 51Orphanet, 36MeSH, 2CDC, 24GTR, 27ICD10, 29ICD9CM, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen
See all MalaCards sources

Aliases & Descriptions for Thalassemia, Hispanic Gamma-Delta-Beta:

Name: Thalassemia, Hispanic Gamma-Delta-Beta 49 11 45
Beta-Thalassemia 68 21 45 22 47 51 67 36
Mediterranean Anemia 68 21 45 22 23 51 67
Cooley's Anemia 68 21 45 22 67 2 65
Beta Thalassemia 10 22 23 12 67 65
Erythroblastic Anemia 68 45 23 67
Thalassemia Major 68 22 47 67
Thalassemia Intermedia 68 22 65
Beta-Thalassemia Major 22 51 24
Beta-Thalassemia Intermedia 51 24
Beta Thalassemia Intermedia 45 65
 
Intermedia Thalassemia 47 24
Thalassemia, Beta Type 23 24
Thalassemias, Beta- 49 45
Thalassemia Minor 67 65
Microcytemia, Beta Type 23
Beta-Thalassemia Minor 24
Beta Thalassemia Minor 45
Beta Thalassemia Major 45
Beta^+^ Thalassemia 65
Cooley Anemia 51
B-Thal 67

Characteristics:

Orphanet epidemiological data:

51
beta-thalassemia:
Inheritance: Autosomal recessive; Prevalence: 1-9/100000 (Worldwide),1-9/1000000 (France),1-5/10000 (Europe); Age of onset: Childhood,Infancy; Age of death: adult
beta-thalassemia intermedia:
Inheritance: Autosomal recessive; Age of onset: Childhood
mediterranean anemia:
Inheritance: Autosomal recessive; Age of onset: Infancy,Neonatal

Classifications:



External Ids:

OMIM49 613985
Disease Ontology10 DOID:12241
ICD1027 D56.1
ICD9CM29 282.44
MeSH36 D017086
NCIt42 C34375
Orphanet51 848, 231222, 231214
ICD10 via Orphanet28 D56.1
MESH via Orphanet37 D017086
UMLS via Orphanet66 C0005283, C0472767
UMLS65 C0005283, C3841475, C0002875 C0271979, C0472767, C0085578, more

Summaries for Thalassemia, Hispanic Gamma-Delta-Beta

About this section
OMIM:49 Beta-thalassemia is characterized by a reduced production of hemoglobin A (HbA, alpha-2/beta-2), which results from the... (613985) more...

MalaCards based summary: Thalassemia, Hispanic Gamma-Delta-Beta, also known as beta-thalassemia, is related to thalassemia-beta, dominant inclusion-body and malaria, and has symptoms including pallor, splenomegaly and hypersplenism. An important gene associated with Thalassemia, Hispanic Gamma-Delta-Beta is HBB (Hemoglobin Subunit Beta), and among its related pathways are HIF-1 signaling pathway and HIF-1-alpha transcription factor network. The drug sodium phenylbutyrate has been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver, and related mouse phenotypes are liver/biliary system and hematopoietic system.

Disease Ontology:10 A thalassemia characterized by the reduced or absent synthesis of the beta globin chains of hemoglobin.

NIH Rare Diseases:45 Beta-thalassemia is a blood disorder that reduces the body's production of hemoglobin. low levels of hemoglobin lead to a shortage of mature red blood cells and a lack of oxygen in the body. affected people have anemia, which can cause paleness, weakness, fatigue, and more serious complications. severe beta-thalassemia is called “thalassemia major” or “cooley’s anemia.” thalassemia intermedia is a less severe form. beta-thalassemia is caused by mutations in the hbb gene and is usually inherited in an autosomal recessive manner. people who have only one hbb gene mutation may have no symptoms or develop mild symptoms, and are said to have thalassemia minor. treatment depends on the severity in each person and may include transfusions, folic acid supplementation, iron chelation, and/or bone marrow transplantation (the only definitive cure). last updated: 7/29/2015

UniProtKB/Swiss-Prot:67 Beta-thalassemia: A form of thalassemia. Thalassemias are common monogenic diseases occurring mostly in Mediterranean and Southeast Asian populations. The hallmark of beta-thalassemia is an imbalance in globin-chain production in the adult HbA molecule. Absence of beta chain causes beta(0)-thalassemia, while reduced amounts of detectable beta globin causes beta(+)-thalassemia. In the severe forms of beta-thalassemia, the excess alpha globin chains accumulate in the developing erythroid precursors in the marrow. Their deposition leads to a vast increase in erythroid apoptosis that in turn causes ineffective erythropoiesis and severe microcytic hypochromic anemia. Clinically, beta-thalassemia is divided into thalassemia major which is transfusion dependent, thalassemia intermedia (of intermediate severity), and thalassemia minor that is asymptomatic.

CDC:2 Thalassemia is an inherited (i.e., passed from parents to children through genes) blood disorder caused when the body doesn’t make enough of a protein called hemoglobin, an important part of red blood cells. Thalassemia is a treatable disorder that can be well-managed with blood transfusions and chelation therapy. It is important for people with thalassemia to learn how to stay healthy.

Genetics Home Reference:23 Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

GeneReviews summary for NBK1426

Related Diseases for Thalassemia, Hispanic Gamma-Delta-Beta

About this section

Diseases related to Thalassemia, Hispanic Gamma-Delta-Beta via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 106)
idRelated DiseaseScoreTop Affiliating Genes
1thalassemia-beta, dominant inclusion-body33.1EPO, G6PD, HBA2, HBB, HBG1, HBG2
2malaria30.2EPO, G6PD, HBA2, HBB, TFRC
3sickle beta thalassemia12.8
4thrombocytopenia with beta-thalassemia, x-linked12.7
5hemoglobin e-beta-thalassemia syndrome12.5
6hemoglobin c-beta-thalassemia syndrome12.5
7hemoglobin lepore-beta-thalassemia syndrome12.5
8hemoglobin s beta-thalassemia12.5
9dominant beta-thalassemia12.5
10hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome12.5
11sickle delta beta thalassemia12.4
12gata1-related thrombocytopenia with beta-thalassemia12.4
13fetal hemoglobin quantitative trait locus 112.1
14thalassemias, alpha-11.6
15hb bart's hydrops fetalis11.5
16thalassemia minor11.4
17actinic prurigo10.5HBA2, HBB
18gaba-transaminase deficiency10.5HBA2, HBB
19baraitser brett piesowicz syndrome10.5HFE, TF
20polycythemia due to hypoxia10.4EPO, HBB
21melanoma10.4
22undetermined early-onset epileptic encephalopathy10.4HFE, TFRC
23thalassemia10.4
24kat6b-related disorders10.4HFE, TFR2
25diarrhea 1, secretory chloride, congenital10.4HFE, TFR2
26insomnia, fatal familial10.4HFE, TF
27malignant parietal pleura tumor10.4EPO, TF, TFRC
28thrombocytosis10.4EPO, HFE, TFRC
29hereditary motor and sensory neuropathy with agenesis of the corpus callosum10.4HFE, TFR2
30speech and communication disorders10.3G6PD, HBG2
31cognitive impairment with or without cerebellar ataxia10.3HBB, TF
32thyroid malformation10.3EPO, HBB, TFRC
33transient neonatal neutropenia10.3EPO, HBA2, KLF1
34methemoglobinemia beta-globin type10.3HFE, TFR2
35hypotrichosis-deafness syndrome10.3HBB, HBD
36hemoglobin e disease10.3HBB, HBD
37cutaneous porphyria10.3GATA1, HFE, TF
38pneumoconiosis due to talc10.3HBB, HFE, TF, TFRC
39leukemia10.3
40inherited metabolic disorder10.3TF, TFRC
41panophthalmitis10.3HBB, HBD
42queensland tick typhus10.2G6PD, HBB, HBG2
43chronic congestive splenomegaly10.2HBB, HBD
44rheumatic fever10.2G6PD, HBB
45basal cell carcinoma10.2HBB, HBD
46gastric cancer10.2
47hepatitis10.2
48prostatitis10.2
49active peptic ulcer disease10.2HBB, HBD
50dfna 3 nonsyndromic hearing loss and deafness10.2GATA1, HBD

Graphical network of the top 20 diseases related to Thalassemia, Hispanic Gamma-Delta-Beta:



Diseases related to thalassemia, hispanic gamma-delta-beta

Symptoms for Thalassemia, Hispanic Gamma-Delta-Beta

About this section


Clinical features from OMIM:

613985

Symptoms:

 51 (show all 52)
  • splenomegaly
  • anomalies of bones/skeletal anomalies
  • anaemia
  • microcytic anemia
  • hemoglobinosis/hemoglobinopathy
  • autosomal recessive inheritance
  • pallor
  • skull/cranial anomalies
  • hepatomegaly/liver enlargement (excluding storage disease)
  • respiratory distress/dyspnea/respiratory failure/lung volume reduction
  • late puberty/hypogonadism/hypogenitalism
  • humour troubles/anxiety/depression/apathy/euphoria/irritability
  • muscle weakness/flaccidity
  • osteoporosis/osteopenia/demineralisation/osteomalacia/rickets
  • hyperferritinemia/iron overload
  • fever/chilling
  • chronic skin infection/ulcerations/ulcers/cancrum
  • biliary/gallbladder stones/lithiasis/cholecystitis
  • hepatitis/icterus/cholestasis
  • cardiomyopathy/hypertrophic/dilated
  • venous thrombosis/phlebitis/thrombophlebitis
  • thrombocytopenia/thrombopenia
  • autosomal dominant inheritance
  • pulmonary hypertension
  • hepatic/liver neoplasm/tumor/carcinoma/cancer
  • hypersplenism
  • upslanted palpebral fissures/mongoloid slanting palpebral fissures
  • prominent premaxillary region/midface
  • depressed nasal bridge
  • anomalies of teeth and dentition
  • genu valgum
  • feeding disorder/dysphagia/swallowing/sucking disorder/esophageal dyskinesia
  • malabsorption/chronic diarrhea/steatorrhea
  • paresthesia/dysesthesia/hypoesthesia/anesthesia/numbness
  • cataract/lens opacification
  • night blindness/hemeralopia
  • mild visual loss/impaired visual acuity
  • achromatopsia/dyschromatopsia/daltonism/impaired colour vision
  • hearing loss/hypoacusia/deafness
  • anomalies of chest/thorax/trunk
  • cirrhosis
  • abnormal hepatic enzymes/transaminases
  • cardiac rhythm disorder/arrhythmia
  • collapse/sudden death/cardiac arrest/cardiorespiratory arrest
  • hypothalamic-hypophyseal axis functional anomalies/hypopituitarism
  • hypothyroidy
  • hypoparathyroidy
  • cortico-adrenal hypoplasia/insufficiency
  • diabetes mellitus
  • dysostosis/chondrodysplasia/osteodysplasia/osteochondrosis/skeletal dysplasia
  • articular/joint pain/arthralgia
  • bone marrow failure/pancytopenia

HPO human phenotypes related to Thalassemia, Hispanic Gamma-Delta-Beta:

(show all 47)
id Description Frequency HPO Source Accession
1 pallor hallmark (90%) HP:0000980
2 splenomegaly hallmark (90%) HP:0001744
3 hypersplenism hallmark (90%) HP:0001971
4 abnormality of the heme biosynthetic pathway hallmark (90%) HP:0010472
5 abnormality of the genital system typical (50%) HP:0000078
6 abnormality of the teeth typical (50%) HP:0000164
7 upslanted palpebral fissure typical (50%) HP:0000582
8 behavioral abnormality typical (50%) HP:0000708
9 biliary tract abnormality typical (50%) HP:0001080
10 muscle weakness typical (50%) HP:0001324
11 malabsorption typical (50%) HP:0002024
12 respiratory insufficiency typical (50%) HP:0002093
13 hepatomegaly typical (50%) HP:0002240
14 genu valgum typical (50%) HP:0002857
15 paresthesia typical (50%) HP:0003401
16 reduced bone mineral density typical (50%) HP:0004349
17 abnormality of temperature regulation typical (50%) HP:0004370
18 depressed nasal bridge typical (50%) HP:0005280
19 feeding difficulties in infancy typical (50%) HP:0008872
20 malar prominence typical (50%) HP:0010620
21 abnormality of iron homeostasis typical (50%) HP:0011031
22 hearing impairment occasional (7.5%) HP:0000365
23 visual impairment occasional (7.5%) HP:0000505
24 cataract occasional (7.5%) HP:0000518
25 abnormality of color vision occasional (7.5%) HP:0000551
26 nyctalopia occasional (7.5%) HP:0000662
27 abnormality of the thorax occasional (7.5%) HP:0000765
28 diabetes mellitus occasional (7.5%) HP:0000819
29 hypothyroidism occasional (7.5%) HP:0000821
30 hypoparathyroidism occasional (7.5%) HP:0000829
31 anterior hypopituitarism occasional (7.5%) HP:0000830
32 biliary tract abnormality occasional (7.5%) HP:0001080
33 cirrhosis occasional (7.5%) HP:0001394
34 hypertrophic cardiomyopathy occasional (7.5%) HP:0001639
35 sudden cardiac death occasional (7.5%) HP:0001645
36 thrombocytopenia occasional (7.5%) HP:0001873
37 pulmonary hypertension occasional (7.5%) HP:0002092
38 skeletal dysplasia occasional (7.5%) HP:0002652
39 arthralgia occasional (7.5%) HP:0002829
40 neoplasm of the liver occasional (7.5%) HP:0002896
41 elevated hepatic transaminases occasional (7.5%) HP:0002910
42 thrombophlebitis occasional (7.5%) HP:0004418
43 bone marrow hypocellularity occasional (7.5%) HP:0005528
44 primary adrenal insufficiency occasional (7.5%) HP:0008207
45 skin ulcer occasional (7.5%) HP:0200042
46 hypochromic microcytic anemia HP:0004840
47 reduced beta/alpha synthesis ratio HP:0011906

Drugs & Therapeutics for Thalassemia, Hispanic Gamma-Delta-Beta

About this section

Drugs for Thalassemia, Hispanic Gamma-Delta-Beta (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 179)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Mycophenolic acidapprovedPhase 4, Phase 2, Phase 189824280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Melbex
 
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolic Acid
Mycophenolsaeure
Myfortic
2
Mycophenolate mofetilapproved, investigationalPhase 4, Phase 2, Phase 1898128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate Mofetil
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
3
DeferiproneapprovedPhase 4, Phase 3, Phase 2, Phase 15330652-11-02972
Synonyms:
1,2-Dimethyl-3-hydroxypyrid-4-one
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
APO-066
CP-20
DN-180-01-AF
Deferipron
 
Deferiprona
Deferiproni
Deferipronum
Deferypron
Dimethylhydroxypyridone
Défériprone
Ferriprox
PL-1
4
Deferoxamineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 14470-51-92973
Synonyms:
DF B
DFO
DFOA
DFOM
Deferoxamide B
Deferoxamin
Deferoxamina
Deferoxamine
Deferoxamine B
Deferoxamine Hydrochloride
 
Deferoxamine Mesylate
Deferoxamine mesylate
Deferoxaminum
Deferrioxamine
Deferrioxamine B
Deferrioxamine b
Desferal
Desferrioxamine
Desferrioxamine B
Déferoxamine
N-Benzoylferrioxamine B
5
IronapprovedPhase 4, Phase 3, Phase 2, Phase 110217439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Dexiron
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Ed-In-Sol
 
Eisen
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feraheme
Feronate
Ferretts
Ferrlecit
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Infufer
Iron
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Yieronia
fer
ferrous ascorbate
ferrous fumarate
ferrous gluconate
ferrous glycine sulfate
ferrous iron
ferrous succinate
ferrous sulfate
hierro
6
Deferasiroxapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 186201530-41-85493381
Synonyms:
Deferasiroxum
Deferasiroxum [inn-latin]
 
Exjade
ICL 670
ICL 670a
deferasirox
7
MethotrexateapprovedPhase 414441959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
Methopterin
Methotextrate
 
Methotrate
Methotrexat
Methotrexate
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metoject
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Otrexup
Rasuvo
Rheumatrex
Rheumatrex Dose Pack
Trexall
8
Miconazoleapproved, investigationalPhase 4, Phase 1, Phase 2302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
9
HyaluronanapprovedPhase 43629067-32-7, 9004-61-953477741, 24759
Synonyms:
Hyaluronate
Hyaluronic acid
Hyaluronic acid sodium salt
Hylartil
Hyruan Plus
Luronit
Macronan
 
Mucoitin
Nutra-HAF
Q 5AQ
Sepracoat
Sepragel Sinus
Sodium hyaluronate
Sofast
Synvisc
10
Daclizumabapproved, investigationalPhase 496152923-56-3
Synonyms:
Anti-IL-2
Humanized antiCD25
 
Ig gamma-1 chain C region
Simulect
chimeric mouse-human antiCD25
11
Peginterferon alfa-2bapprovedPhase 429999210-65-8
Synonyms:
215647-85-1
D02748
PEG-Intron
PegIntron
Peginterferon alfa-2b
 
Peginterferon alfa-2b (INN)
Peginterferon alfa-2b (generical recombination)
Peginterferon alfa-2b (generical recombination) (JAN)
Pegintron
Pegintron (TN)
Sylatron
Unitron PEG
12
RibavirinapprovedPhase 494836791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
Ibavyr
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
Moderiba
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
 
NSC 163039
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribasphere Ribapak
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
13
Peginterferon alfa-2aapproved, investigationalPhase 4537198153-51-45360545
Synonyms:
198153-51-4
D02747
Pegasys
 
Pegasys (TN)
Peginterferon alfa-2a
Peginterferon alfa-2a (USAN/INN)
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
14
Folic Acidapproved, nutraceuticalPhase 4292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
15
Ergocalciferolapproved, nutraceuticalPhase 492350-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
16
Cholecalciferolapproved, nutraceuticalPhase 479967-97-06221, 10883523, 5280795
Synonyms:
()-Vitamin D3
(+)-Vitamin D3
(+)-vitamin D3
(1S,3Z)-3-[(2e)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7e)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7e)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol
47763_SUPELCO
57651-82-8
67-97-0
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
9,10-Secocholesta-5,7,10(19)-trien-3-ol
9,10-Secocholesta-5,7,10-trien-3-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
Activated 7-dehydrocholesterol
Arachitol
BPBio1_000460
BSPBio_000418
BSPBio_002408
Bio-0845
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
CID7067440
CID7251172
CID7251174
CID9821465
Calciol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol D3
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferolum
 
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Devaron
DivK1c_006276
Duphafral D3 1000
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
Ebivit
FeraCol
Granuvit D3
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC-375571
NSC375571
Oleovitamin D3
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Prestwick_63
Provitamine
Provitina
Quintox
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SR-05000001559
SR-05000001559-3
ST057172
SpecPlus_000180
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
Spectrum_001163
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
VITAMIN D
VITAMIN D3 POWDER
VITAMIN_D3
Vi-De3
Vi-de-3-hydrosol
VidDe-3-hydrosol
Videkhol
Vigantol
Vigorsan
Vitamin D3
Vitamin D3 emulsifiable
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
bmse000507
calciol
cholecalciferol
delta-D
vitamin d-3
17Antiviral AgentsPhase 48071
18Liver ExtractsPhase 4, Phase 2, Phase 3, Phase 13572
19Protective AgentsPhase 4, Phase 2, Phase 3, Phase 15651
20Anti-Bacterial AgentsPhase 4, Phase 2, Phase 19140
21Adjuvants, ImmunologicPhase 41783
22Iron Chelating AgentsPhase 4, Phase 3, Phase 2, Phase 1178
23Antirheumatic AgentsPhase 4, Phase 2, Phase 18496
24MicronutrientsPhase 4, Phase 2, Phase 33901
25VitaminsPhase 4, Phase 2, Phase 33857
26Chelating AgentsPhase 4, Phase 3, Phase 2, Phase 1667
27Nucleic Acid Synthesis InhibitorsPhase 4, Phase 2, Phase 3, Phase 13836
28Trace ElementsPhase 4, Phase 2, Phase 33900
29Calcium, DietaryPhase 4, Phase 2, Phase 34678
30AntimetabolitesPhase 4, Phase 2, Phase 19454
31Anti-Infective AgentsPhase 4, Phase 1, Phase 217220
32Immunosuppressive AgentsPhase 4, Phase 2, Phase 110422
33Immunologic FactorsPhase 4, Phase 2, Phase 118483
34Antimetabolites, AntineoplasticPhase 4, Phase 2, Phase 15770
35Antibiotics, AntitubercularPhase 4, Phase 2, Phase 15971
36CyclosporinsPhase 4, Phase 2, Phase 1873
37Dermatologic AgentsPhase 4, Phase 1, Phase 24555
38AntibodiesPhase 44477
39VaccinesPhase 46085
40Vitamin B ComplexPhase 42847
41Folic Acid AntagonistsPhase 41643
42Calcineurin InhibitorsPhase 4, Phase 1, Phase 21223
43Antifungal AgentsPhase 4, Phase 1, Phase 23015
44interferonsPhase 41930
45Hepatitis C AntibodiesPhase 455
46ImmunoglobulinsPhase 44477
47Interferon-alphaPhase 41028
48ViscosupplementsPhase 4267
49Bone Density Conservation AgentsPhase 4, Phase 2, Phase 32600
50Heptavalent Pneumococcal Conjugate VaccinePhase 4440

Interventional clinical trials:

(show top 50)    (show all 161)
idNameStatusNCT IDPhase
1Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron OverloadCompletedNCT00564941Phase 4
2Post Hematopoietic Stem Cell TransplantationCompletedNCT01610297Phase 4
3Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)CompletedNCT00171301Phase 4
4Efficacy Study of the Use of Sequential DFP-DFO Versus DFPCompletedNCT00733811Phase 4
5Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia MajorCompletedNCT00800761Phase 4
6Efficacy Study in Removing Excess Iron From the HeartCompletedNCT00105495Phase 4
7Pilot Study for Patients With Poor Response to DeferasiroxCompletedNCT00749515Phase 4
8Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia MajorRecruitingNCT02342145Phase 4
9the Potential Immunomodulatory Effects of Spirulina on Thalassemic ChildrenRecruitingNCT02674607Phase 4
10Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis CRecruitingNCT02744560Phase 4
11Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis CRecruitingNCT02744547Phase 4
12Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis CRecruitingNCT02744105Phase 4
13Interferon and Ribavirin Treatment in Patients With HemoglobinopathiesRecruitingNCT00887081Phase 4
14Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia MajorActive, not recruitingNCT02597595Phase 4
15Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia MajorActive, not recruitingNCT00103753Phase 4
16B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic IndividualsActive, not recruitingNCT01846923Phase 4
17The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response StudyNot yet recruitingNCT01323608Phase 4
18An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years OldWithdrawnNCT01724138Phase 4
19An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron OverloadCompletedNCT00171210Phase 3
20A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisCompletedNCT00171171Phase 3
21Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia MajorCompletedNCT01125254Phase 2, Phase 3
22Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00061750Phase 3
23Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia MajorCompletedNCT01395199Phase 3
24Effect of Metoprolol on Thalassemia CardiomyopathyCompletedNCT01863173Phase 2, Phase 3
25Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension StudyCompletedNCT01033747Phase 2, Phase 3
26Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedNCT00943748Phase 2, Phase 3
27Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC TransfusionRecruitingNCT01740531Phase 3
28An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) ThalassemiaRecruitingNCT02604433Phase 3
29Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric PatientsRecruitingNCT01825512Phase 3
30Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron StoresRecruitingNCT00658164Phase 3
31Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major PatientsActive, not recruitingNCT01016093Phase 2, Phase 3
32Therapeutic Effects of Silymarin in Patients With B-thalassemia MajorActive, not recruitingNCT00999349Phase 2, Phase 3
33Long-term Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene TherapyEnrolling by invitationNCT02633943Phase 2, Phase 3
34An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major PatientsNot yet recruitingNCT02173951Phase 2, Phase 3
35Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron OverloadNot yet recruitingNCT01511848Phase 2, Phase 3
36Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.Not yet recruitingNCT01624038Phase 2, Phase 3
37Role of Vitamin C to Augment Iron Chelation With DFP or DFXNot yet recruitingNCT02083575Phase 2, Phase 3
38Trial of HQK-1001 in Beta Thalassemia Intermedia in LebanonCompletedNCT01642758Phase 2
39Cardiac T2* in Beta-thalassemia Patients on Deferasirox TreatmentCompletedNCT00447694Phase 2
40Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)CompletedNCT00001958Phase 2
41A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.CompletedNCT00390858Phase 2
42Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia IntermediaCompletedNCT00809042Phase 2
43Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in ThailandCompletedNCT01609595Phase 2
44Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-ThalassemiaCompletedNCT00069862Phase 1, Phase 2
45Phase 1/2 Study of HQK-1001 in Patients With Beta ThalassemiaCompletedNCT00790127Phase 1, Phase 2
46Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron OverloadCompletedNCT01459718Phase 2
47Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic AnemiasCompletedNCT00061763Phase 2
48Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia PatientsCompletedNCT00303329Phase 2
49Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia IntermediaCompletedNCT00006136Phase 2
50Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TICompletedNCT01140321Phase 2

Search NIH Clinical Center for Thalassemia, Hispanic Gamma-Delta-Beta

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: beta-thalassemia

Genetic Tests for Thalassemia, Hispanic Gamma-Delta-Beta

About this section

Genetic tests related to Thalassemia, Hispanic Gamma-Delta-Beta:

id Genetic test Affiliating Genes
1 Beta-Thalassemia22 HBB
2 Thalassemia Intermedia22
3 Thalassemia Major22

Anatomical Context for Thalassemia, Hispanic Gamma-Delta-Beta

About this section

MalaCards organs/tissues related to Thalassemia, Hispanic Gamma-Delta-Beta:

33
Bone, Bone marrow, Liver, Heart, Skin, Lung, Testes

Animal Models for Thalassemia, Hispanic Gamma-Delta-Beta or affiliated genes

About this section

MGI Mouse Phenotypes related to Thalassemia, Hispanic Gamma-Delta-Beta:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.4EPO, GATA1, HFE, KLF1, SPTB, TFR2
2MP:00053977.1EPO, G6PD, GATA1, HFE, KLF1, RHD

Publications for Thalassemia, Hispanic Gamma-Delta-Beta

About this section

Variations for Thalassemia, Hispanic Gamma-Delta-Beta

About this section

UniProtKB/Swiss-Prot genetic disease variations for Thalassemia, Hispanic Gamma-Delta-Beta:

67
id Symbol AA change Variation ID SNP ID
1HBBp.Glu27LysVAR_002907
2HBBp.Ala116AspVAR_003037
3HBBp.Val127GlyVAR_003056
4HBBp.Leu115ProVAR_010145

Clinvar genetic disease variations for Thalassemia, Hispanic Gamma-Delta-Beta:

5 (show all 40)
id Gene Variation Type Significance SNP ID Assembly Location
1HBBNM_000518.4(HBB): c.364G> C (p.Glu122Gln)single nucleotide variantPathogenicrs33946267GRCh37Chr 11, 5246908: 5246908
2HBBNM_000518.4(HBB): c.92G> C (p.Arg31Thr)single nucleotide variantPathogenicrs33960103GRCh37Chr 11, 5248160: 5248160
3HBBNM_000518.4(HBB): c.82G> T (p.Ala28Ser)single nucleotide variantLikely pathogenic, Pathogenicrs35424040GRCh37Chr 11, 5248170: 5248170
4HBBNM_000518.4(HBB): c.364G> A (p.Glu122Lys)single nucleotide variantPathogenicrs33946267GRCh37Chr 11, 5246908: 5246908
5HBBNM_000518.4(HBB): c.364G> A (p.Glu122Lys)single nucleotide variantPathogenicrs33946267GRCh37Chr 11, 5246908: 5246908
6HBBNM_000518.4(HBB): c.328G> A (p.Val110Met)single nucleotide variantLikely pathogenicrs33969677GRCh37Chr 11, 5246944: 5246944
7HBBNM_000518.4(HBB): c.364G> C (p.Glu122Gln)single nucleotide variantPathogenicrs33946267GRCh37Chr 11, 5246908: 5246908
8HBBNM_000518.4(HBB): c.114G> A (p.Trp38Ter)single nucleotide variantLikely pathogenic, Pathogenicrs33974936GRCh37Chr 11, 5248008: 5248008
9HBBNM_000518.4(HBB): c.25_26delAA (p.Lys9Valfs)deletionPathogenicrs35497102GRCh37Chr 11, 5248226: 5248227
10HBBNM_000518.4(HBB): c.51delC (p.Lys18Argfs)deletionPathogenicrs35662066GRCh37Chr 11, 5248201: 5248201
11HBBNM_000518.4(HBB): c.135delC (p.Phe46Leufs)deletionPathogenicrs80356820GRCh37Chr 11, 5247987: 5247987
12HBBNM_000518.4(HBB): c.230delC (p.Ala77Valfs)deletionLikely pathogenic, Pathogenicrs281864901GRCh37Chr 11, 5247892: 5247892
13HBBNM_000518.4(HBB): c.85dupC (p.Leu29Profs)duplicationLikely pathogenic, Pathogenicrs35532010GRCh37Chr 11, 5248168: 5248168
14HBBNM_000518.4(HBB): c.92+1G> Tsingle nucleotide variantLikely pathogenic, Pathogenicrs33971440GRCh37Chr 11, 5248159: 5248159
15HBBNM_000518.4(HBB): c.93-22_95del25deletionPathogenicrs193922563GRCh37Chr 11, 5248027: 5248051
16HBBNM_000518.4(HBB): c.92+5G> Asingle nucleotide variantLikely pathogenic, Pathogenicrs33915217GRCh37Chr 11, 5248155: 5248155
17HBBNM_000518.4(HBB): c.316-106C> Gsingle nucleotide variantPathogenicrs34690599GRCh37Chr 11, 5247062: 5247062
18HBBNM_000518.4(HBB): c.75T> A (p.Gly25=)single nucleotide variantPathogenicrs33951465GRCh37Chr 11, 5248177: 5248177
19HBBNM_000518.4(HBB): c.-50-101C> Tsingle nucleotide variantPathogenicrs63751208GRCh37Chr 11, 5248402: 5248402
20HBBNM_000518.4(HBB): c.-136C> Gsingle nucleotide variantPathogenicrs33994806GRCh37Chr 11, 5248387: 5248387
21HBBNM_000518.4(HBB): c.-80T> Asingle nucleotide variantPathogenicrs33980857GRCh37Chr 11, 5248331: 5248331
22HBBNM_000518.4(HBB): c.-78A> Gsingle nucleotide variantPathogenicrs33931746GRCh37Chr 11, 5248329: 5248329
23HBBNM_000518.4(HBB): c.143dupA (p.Asp48Glufs)duplicationPathogenicrs35894115GRCh37Chr 11, 5247979: 5247979
24HBBNM_000518.4(HBB): c.364G> C (p.Glu122Gln)single nucleotide variantPathogenicrs33946267GRCh37Chr 11, 5246908: 5246908
25HBBNM_000518.4(HBB): c.-140C> Tsingle nucleotide variantLikely pathogenic, Pathogenicrs34999973GRCh37Chr 11, 5248391: 5248391
26HBBNM_000518.4(HBB): c.116_117delCC (p.Gln40Glufs)deletionPathogenicrs267607298GRCh37Chr 11, 5248005: 5248006
27HBBNM_000518.4(HBB): c.364G> C (p.Glu122Gln)single nucleotide variantPathogenicrs33946267GRCh37Chr 11, 5246908: 5246908
28HBBNM_000518.4(HBB): c.364G> A (p.Glu122Lys)single nucleotide variantPathogenicrs33946267GRCh37Chr 11, 5246908: 5246908
29HBBNM_000518.4(HBB): c.315+1G> Csingle nucleotide variantLikely pathogenicrs33945777GRCh38Chr 11, 5226576: 5226576
30HBBNM_000518.4(HBB): c.-136C> Tsingle nucleotide variantLikely pathogenicrs33994806GRCh37Chr 11, 5248387: 5248387
31HBBNM_000518.4(HBB): c.-50A> Csingle nucleotide variantLikely pathogenicrs34305195GRCh37Chr 11, 5248301: 5248301
32HBBNM_000518.4(HBB): c.19_20delGAinsAT (p.Glu7Met)indelLikely pathogenicrs193922552GRCh37Chr 11, 5248232: 5248233
33HBBNM_000518.4(HBB): c.251delG (p.Gly84Alafs)deletionLikely pathogenic, Pathogenicrs193922555GRCh37Chr 11, 5247871: 5247871
34HBBNM_000518.4(HBB): c.27dupG (p.Ser10Valfs*14)duplicationPathogenicrs35699606GRCh37Chr 11, 5248225: 5248225
35HBBNM_000518.4(HBB): c.287dupA (p.Leu97Alafs)duplicationLikely pathogenicrs34937014GRCh37Chr 11, 5247835: 5247835
36HBBNM_000518.4(HBB): c.2T> C (p.Met1Thr)single nucleotide variantLikely pathogenic, Pathogenicrs33941849GRCh37Chr 11, 5248250: 5248250
37HBBNM_000518.4(HBB): c.316-14T> Gsingle nucleotide variantPathogenicrs35703285GRCh37Chr 11, 5246970: 5246970
38HBBNM_000518.4(HBB): c.92+2T> Csingle nucleotide variantPathogenicrs33956879GRCh37Chr 11, 5248158: 5248158
39HBBNM_000518.4(HBB): c.92G> A (p.Arg31Lys)single nucleotide variantLikely pathogenicrs33960103GRCh37Chr 11, 5248160: 5248160
40HBBNM_000518.4(HBB): c.93-3T> Gsingle nucleotide variantLikely pathogenicrs34527846GRCh37Chr 11, 5248032: 5248032

Expression for genes affiliated with Thalassemia, Hispanic Gamma-Delta-Beta

About this section
Search GEO for disease gene expression data for Thalassemia, Hispanic Gamma-Delta-Beta.

Pathways for genes affiliated with Thalassemia, Hispanic Gamma-Delta-Beta

About this section

Pathways related to Thalassemia, Hispanic Gamma-Delta-Beta according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.8EPO, TF, TFRC
29.8EPO, TF, TFRC
39.6TF, TFR2, TFRC
47.9GATA1, HBB, HBD, HBE1, HBG1, HBG2

GO Terms for genes affiliated with Thalassemia, Hispanic Gamma-Delta-Beta

About this section

Cellular components related to Thalassemia, Hispanic Gamma-Delta-Beta according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1haptoglobin-hemoglobin complexGO:003183810.1HBA2, HBB
2hemoglobin complexGO:00058339.0HBD, HBG1, HBG2

Biological processes related to Thalassemia, Hispanic Gamma-Delta-Beta according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1erythrocyte maturationGO:004324910.3EPO, G6PD
2positive regulation of peptide hormone secretionGO:009027710.3HFE, TFR2
3response to iron ionGO:001003910.1HFE, TFR2
4erythrocyte differentiationGO:00302189.9EPO, KLF1
5iron ion homeostasisGO:00550729.7HFE, TF, TFR2
6cellular iron ion homeostasisGO:00068799.7TF, TFR2, TFRC
7receptor-mediated endocytosisGO:00068989.6HBA2, HBB, TFRC
8acute-phase responseGO:00069539.5EPO, HFE, TFRC, UGT1A1

Molecular functions related to Thalassemia, Hispanic Gamma-Delta-Beta according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1haptoglobin bindingGO:003172010.4HBA2, HBB
2peroxidase activityGO:000460110.1HBA2, HBB
3oxygen bindingGO:00198258.5HBD, HBE1, HBG1, HBG2
4oxygen transporter activityGO:00053448.3HBA2, HBD, HBE1, HBG1, HBG2

Sources for Thalassemia, Hispanic Gamma-Delta-Beta

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet